argenx (ARGX) Added to Wedbush Best Ideas List

Go back to argenx (ARGX) Added to Wedbush Best Ideas List

Piper Jaffray Reiterates Overweight on argenx (ARGX) Following Efgartigimod Data

September 24, 2018 7:09 AM EDT

Piper Jaffray analyst, Edward Tenthoff, reiterated an Overweight rating and $154.00 price target on argenx SE (NASDAQ: ARGX) following the company's positive Phase II Immune Thrombocytopenia data on efgartigimod. The data showed clean safety and clear efficacy. Tenthoff expects full data at ASH in... More